NO974275L - Fremgangsmåte for behandling av tumorer - Google Patents

Fremgangsmåte for behandling av tumorer

Info

Publication number
NO974275L
NO974275L NO974275A NO974275A NO974275L NO 974275 L NO974275 L NO 974275L NO 974275 A NO974275 A NO 974275A NO 974275 A NO974275 A NO 974275A NO 974275 L NO974275 L NO 974275L
Authority
NO
Norway
Prior art keywords
patient
lymphocytes
treating tumors
preferred
donor lymphocytes
Prior art date
Application number
NO974275A
Other languages
English (en)
Other versions
NO974275D0 (no
Inventor
Gale A Granger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO974275D0 publication Critical patent/NO974275D0/no
Publication of NO974275L publication Critical patent/NO974275L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Det blir beskrevet en fremgangsmåte for behandling av en mammalsk pasient som har en tumor ved administrering til pasienten av allogeniske donorlymfocytter som har blitt samdyrket i nærvær av pasientavlede lymfocytter under betingelser som er tilstrekkelige for å alloaktivere donorlymfocyttene. Det er foretrukket at donorlymfocyttene blir inn- ført intralesjonalt. Denne fremgangsmåten er foretrukket forbehandling av glioblastoma i mennesker.
NO974275A 1995-03-17 1997-09-16 Fremgangsmåte for behandling av tumorer NO974275L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40638895A 1995-03-17 1995-03-17
PCT/US1996/003621 WO1996029394A1 (en) 1995-03-17 1996-03-15 Method for treating tumors

Publications (2)

Publication Number Publication Date
NO974275D0 NO974275D0 (no) 1997-09-16
NO974275L true NO974275L (no) 1997-10-15

Family

ID=23607777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974275A NO974275L (no) 1995-03-17 1997-09-16 Fremgangsmåte for behandling av tumorer

Country Status (11)

Country Link
US (2) US5837233A (no)
EP (1) EP0815204B1 (no)
JP (1) JP3201610B2 (no)
KR (1) KR19980703072A (no)
AT (1) ATE338813T1 (no)
AU (1) AU696572B2 (no)
BR (1) BR9607894A (no)
CA (1) CA2214503C (no)
DE (1) DE69636514D1 (no)
NO (1) NO974275L (no)
WO (1) WO1996029394A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CN1237909A (zh) * 1996-10-11 1999-12-08 加利福尼亚大学董事会 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
WO1998048000A2 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of California A cell strain with activated anti-cancer cytotoxic activity
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
WO1999018981A1 (en) * 1997-10-10 1999-04-22 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
AU9589398A (en) 1997-10-10 1999-05-03 Applied Immunotherapeutics, Inc. Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
JP2002539271A (ja) 1999-03-24 2002-11-19 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ 神経膠芽腫培養物上澄み（ｇｃｓ）による抗原特異的非応答性の誘導
US6719805B1 (en) * 1999-06-09 2004-04-13 C. R. Bard, Inc. Devices and methods for treating tissue
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
JP2004523202A (ja) * 2000-06-09 2004-08-05 ウニベルジテートスクリーニクム シャリテー メディツィニーシェ ファクルテート デル フンボルト−ウニベルジテート ツー ベルリン，アカデミッシェ ファーバルツング−フォルシュン 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
DE10120505A1 (de) 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US8691568B2 (en) 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
US8455188B2 (en) * 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
RU2548741C2 (ru) * 2009-03-05 2015-04-20 Макрокьюэ, Лтд. Активированная лейкоцитарная композиция
JP5816627B2 (ja) 2009-10-27 2015-11-18 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
MY189857A (en) 2014-11-05 2022-03-14 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2018138682A1 (en) 2017-01-26 2018-08-02 Immune Therapeutics Methods and compositions useful for treating cancer
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038145A (en) * 1974-07-08 1977-07-26 Mead Johnson & Company Malignancy diagnostic method
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
DK0552243T3 (da) * 1990-09-06 1997-03-10 Schering Corp Anvendelse af interleukin-4 til behandling af faste tumorer
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
EP0815204A4 (en) 1999-04-14
WO1996029394A1 (en) 1996-09-26
MX9707077A (es) 1998-08-30
US6136306A (en) 2000-10-24
KR19980703072A (ko) 1998-09-05
DE69636514D1 (de) 2006-10-19
CA2214503C (en) 2002-05-07
BR9607894A (pt) 1999-06-01
JP3201610B2 (ja) 2001-08-27
EP0815204B1 (en) 2006-09-06
ATE338813T1 (de) 2006-09-15
NO974275D0 (no) 1997-09-16
EP0815204A1 (en) 1998-01-07
AU5254796A (en) 1996-10-08
AU696572B2 (en) 1998-09-10
JPH11501656A (ja) 1999-02-09
CA2214503A1 (en) 1996-09-26
US5837233A (en) 1998-11-17

Similar Documents

Publication Publication Date Title
NO974275L (no) Fremgangsmåte for behandling av tumorer
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
ATE281840T1 (de) Behandlung von diarrhoe
DE69424537D1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
PL328858A1 (en) Immunogenous peptides
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
EP1098642A4 (en) METHODS OF TREATING MODULATED CONDITIONS WITH LACTOSYLCERAMIDE
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
NO984446L (no) FremgangsmÕte for behandling av smerte
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
TR200003225T2 (tr) Bağışıklık tepkisini modüle etmek için yöntemler ve araçlar
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
EA199900091A1 (ru) Терапевтическое применение t-bam(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры
NO970803L (no) Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer
DE69229436D1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application